Monopar Therapeutics Inc Stock Price, News & Analysis

Monopar Therapeutics (Nasdaq: MNPR) has provided an update on its Validive Phase 2b/3 VOICE clinical trial aimed at preventing severe oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer. The company has enrolled over 130 patients, completed the Phase 2b enrollment, and activated 68 sites, including expansions into Germany and Poland. An interim analysis of the Phase 2b data will guide further enrollment in Phase 3, expected to yield results in Q1 2023.

Monopar Therapeutics (Nasdaq: MNPR), a clinical-stage biopharmaceutical company, announced its CEO, Chandler Robinson, will present at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, at 12:00 p.m. (ET). The conference will be held at The Yale Club, New York City.

Monopar focuses on developing therapeutics aimed at improving the quality of life for cancer patients, with a pipeline that includes Validive® and camsirubicin for different cancer treatments. For more information, visit www.monopartx.com.

Monopar Therapeutics (Nasdaq: MNPR) reported second quarter 2022 results, announcing ongoing advancements in their clinical programs. They are actively recruiting for the Validive Phase 2b/3 VOICE trial, now with 58 sites, with an interim analysis expected in Q1 2023. The Camsirubicin trial has progressed to the fourth dose level, showing early clinical benefits. Cash reserves of $16.5 million will fund operations through September 2023, while a net loss of $2.8 million was reported for the quarter. The company aims to secure additional funding for future developments.

Monopar Therapeutics (MNPR) reported first-quarter 2022 financial results, posting a net loss of $2.5 million, or $0.19 per share, compared to $1.9 million, or $0.16 per share in Q1 2021. Cash and equivalents stand at $17.8 million, expected to fund ongoing clinical trials through at least June 2023. The company is actively enrolling patients in its Phase 2b/3 VOICE trial and advancing its camsirubicin Phase 1b dose-escalation trial, which has shown early signs of clinical benefit.

Monopar Therapeutics (NASDAQ: MNPR) reported its fourth quarter and full-year 2021 financial results and highlighted significant advancements in its clinical trials. The company is actively recruiting for the Phase 2b/3 VOICE trial of Validive, aimed at preventing severe oral mucositis in oropharyngeal cancer patients. The trial now includes 44 sites across the U.S. and Europe. Additionally, the Phase 1b trial of camsirubicin is advancing into its third dose level, with early signs of clinical benefit. Cash reserves of $20.3 million are expected to support clinical operations through March 2023.

Monopar Therapeutics (Nasdaq: MNPR) announces that CEO Chandler Robinson will present at two upcoming conferences. The 34th Annual Roth Conference is scheduled for March 14, 2022, at 1:30 PM Pacific Time, at The Ritz Carlton in Laguna Niguel, California. The Maxim’s 2022 Virtual Growth Conference will take place on March 30, 2022, at 4:30 PM Eastern Time. Monopar focuses on therapeutics aimed at improving the lives of cancer patients, with a pipeline that includes Validive® and camsirubicin.

Monopar Therapeutics Inc. (Nasdaq: MNPR) announced significant updates regarding its clinical trials. The Validive Phase 2b/3 VOICE trial is now active at 43 sites in the US and EU, focusing on preventing severe oral mucositis (SOM) in oropharyngeal cancer patients undergoing chemoradiotherapy. Additionally, early signs of clinical benefit were observed in the open-label Phase 1b trial for camsirubicin, aimed at treating advanced soft tissue sarcoma. The company is also advancing its radiopharmaceutical platform and MNPR-202 in preclinical studies.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a biopharmaceutical company focused on cancer therapeutics, announced that CEO Chandler Robinson, MD, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting January 10, 2022, at 7:00am ET.

Monopar's pipeline includes Validive® for severe oral mucositis in oropharyngeal cancer, camsirubicin for advanced soft tissue sarcoma, and other promising candidates targeting advanced cancers and COVID-19.

Monopar Therapeutics (MNPR) has received a positive recommendation from its safety review committee to escalate to the second dose level in the camsirubicin Phase 1b trial for advanced soft tissue sarcoma. This decision follows safety data review from the initial dose cohort, allowing the evaluation of a higher dose of camsirubicin.

Camsirubicin, an analog of doxorubicin, has shown potential anti-tumor activity without the severe cardiotoxicity common to doxorubicin. The trial is actively enrolling patients, with results expected to enhance treatment options for cancer patients.